Kymera Therapeutics, Inc. Financials
Kymera Therapeutics, Inc. (KYMR) reported $39.2M in revenue for fiscal year 2025, down 16.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Kymera’s development-stage model relies on heavy R&D and operating cash use, financed increasingly through external capital.
FY2025 paired reported net income of$311M with operating cash flow of-$232.9M , making net income a poor proxy for operating cash needs in this dataset. With R&D at$316.6M against revenue of$39.2M , the company is funding a development engine rather than a self-financing commercial operation.
Cash rose from
Capital expenditures were just
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Kymera Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Kymera Therapeutics, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 17/100.
Kymera Therapeutics, Inc.'s revenue declined 16.7% year-over-year, from $47.1M to $39.2M. This contraction results in a growth score of 3/100.
Kymera Therapeutics, Inc. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 10.47, Kymera Therapeutics, Inc. holds $10.47 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.
Kymera Therapeutics, Inc.'s reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 3/100.
Kymera Therapeutics, Inc.'s ROE of 19.7% shows moderate profitability relative to equity, earning a score of 33/100. This is down from 26.8% the prior year.
Kymera Therapeutics, Inc. scores 37.36, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($10.4B) relative to total liabilities ($163.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Kymera Therapeutics, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Kymera Therapeutics, Inc. used $0.75 of operating cash (-$232.9M OCF vs $311.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Kymera Therapeutics, Inc. generated $39.2M in revenue in fiscal year 2025. This represents a decrease of 16.7% from the prior year.
Kymera Therapeutics, Inc.'s EBITDA was -$341.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 34.1% from the prior year.
Kymera Therapeutics, Inc. reported $311.4M in net income in fiscal year 2025. This represents an increase of 39.1% from the prior year.
Kymera Therapeutics, Inc. earned -$3.69 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 23.8% from the prior year.
Cash & Balance Sheet
Kymera Therapeutics, Inc. recorded an outflow of $234.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 13.0% from the prior year.
Kymera Therapeutics, Inc. held $357.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Kymera Therapeutics, Inc.'s gross margin was 0.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. That is unchanged from the prior year.
Kymera Therapeutics, Inc.'s ROE was 19.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 7.1 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Kymera Therapeutics, Inc. invested $316.6M in research and development in fiscal year 2025. This represents an increase of 31.8% from the prior year.
Kymera Therapeutics, Inc. invested $1.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 88.7% from the prior year.
Not reported for fiscal year 2025.
KYMR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105.0M | $39.2M-16.7% | $47.1M-40.1% | $78.6M+67.8% | $46.8M-35.7% | $72.8M+114.0% | $34.0M+1060.0% | $2.9M |
| Cost of Revenue | $105.0M | $39.2M-16.7% | $47.1M-40.1% | $78.6M+67.8% | $46.8M | N/A | N/A | N/A |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | N/A | N/A | N/A |
| R&D Expenses | $375.6M | $316.6M+31.8% | $240.2M+27.1% | $189.1M+15.1% | $164.2M+19.9% | $137.0M+120.6% | $62.1M+67.1% | $37.2M |
| SG&A Expenses | $75.8M | $68.2M+7.3% | $63.5M+15.4% | $55.0M+25.6% | $43.8M+20.6% | $36.3M+99.3% | $18.2M+128.5% | $8.0M |
| Operating Income | -$350.2M | -$349.4M-33.5% | -$261.6M-58.1% | -$165.5M-2.7% | -$161.3M-60.4% | -$100.5M-117.1% | -$46.3M-9.7% | -$42.2M |
| Income Tax | N/A | $0 | N/A | N/A | $0 | $0 | $0 | $0 |
| Net Income | $323.1M | $311.4M+39.1% | $223.9M+52.3% | $147.0M-5.1% | $154.8M+54.5% | $100.2M+319.8% | -$45.6M-10.5% | -$41.2M |
| EPS (Diluted) | — | -$3.69-23.8% | -$2.98-18.3% | -$2.52+12.2% | -$2.87-37.3% | -$2.09+33.7% | -$3.15 | N/A |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KYMR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $1.7B+78.2% | $978.0M+69.9% | $575.8M-4.5% | $603.1M-0.5% | $605.9M+24.4% | $487.2M+317.5% | $116.7M |
| Current Assets | $871.2M+70.7% | $510.3M+25.9% | $405.3M-3.4% | $419.4M-7.1% | $451.3M+49.3% | $302.3M+225.6% | $92.8M |
| Cash & Equivalents | $357.0M+196.9% | $120.3M+9.4% | $110.0M+60.8% | $68.4M+42.6% | $48.0M+54.7% | $31.0M-59.2% | $76.0M |
| Accounts Receivable | $0 | $0-100.0% | $15.0M | $0 | N/A | N/A | N/A |
| Total Liabilities | $163.1M+14.6% | $142.4M-21.2% | $180.8M+60.0% | $113.0M-22.8% | $146.3M-28.0% | $203.3M+6.4% | $191.1M |
| Current Liabilities | $83.2M+22.8% | $67.8M-20.9% | $85.7M+20.1% | $71.3M-22.9% | $92.5M-16.3% | $110.6M+220.0% | $34.6M |
| Total Equity | $1.6B+89.0% | $835.6M+111.6% | $395.0M-19.4% | $490.2M+6.6% | $459.6M+61.9% | $283.9M+481.5% | -$74.4M |
| Retained Earnings | -$1.1B-41.3% | -$754.6M-42.2% | -$530.8M-38.3% | -$383.8M-67.6% | -$229.0M-77.8% | -$128.8M-68.4% | -$76.5M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
KYMR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$236.8M | -$232.9M-19.7% | -$194.5M-89.2% | -$102.8M+32.8% | -$153.1M-18.7% | -$128.9M-246.3% | $88.1M+392.2% | $17.9M |
| Capital Expenditures | $1.2M | $1.4M-88.7% | $12.8M-62.8% | $34.5M+1115.8% | $2.8M+77.6% | $1.6M-82.4% | $9.1M+1609.8% | $532K |
| Free Cash Flow | -$238.0M | -$234.3M-13.0% | -$207.3M-51.0% | -$137.3M+11.9% | -$155.9M-19.4% | -$130.5M-265.2% | $79.0M+354.9% | $17.4M |
| Investing Cash Flow | -$752.5M | -$521.1M-29.0% | -$404.1M-388.9% | $139.9M+581.7% | $20.5M+120.6% | -$99.8M+76.4% | -$422.6M-2463.3% | -$16.5M |
| Financing Cash Flow | $777.9M | $990.7M+62.7% | $608.9M+14424.1% | $4.2M-97.3% | $153.0M-38.9% | $250.3M-13.5% | $289.3M+728.6% | $34.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KYMR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0% | N/A | N/A | N/A |
| Operating Margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1438.5% |
| Net Margin | 794.0% | 475.6% | 187.0% | 330.6% | 137.6% | -134.0% | -1405.8% |
| Return on Equity | 19.7%-7.1pp | 26.8%-10.4pp | 37.2%+5.6pp | 31.6%+9.8pp | 21.8%+37.9pp | -16.1% | N/A |
| Return on Assets | 17.9%-5.0pp | 22.9%-2.6pp | 25.5%-0.2pp | 25.7%+9.1pp | 16.5%+25.9pp | -9.4%+26.0pp | -35.3% |
| Current Ratio | 10.47+2.9x | 7.53+2.8x | 4.73-1.1x | 5.88+1.0x | 4.88+2.1x | 2.730.0x | 2.69 |
| Debt-to-Equity | 0.10-0.1x | 0.17-0.3x | 0.46+0.2x | 0.23-0.1x | 0.32-0.4x | 0.72 | N/A |
| FCF Margin | -597.6% | -440.5% | -174.7% | -333.0% | -179.2% | 232.2% | 592.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Kymera Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Kymera Therapeutics, Inc.'s annual revenue?
Kymera Therapeutics, Inc. (KYMR) reported $39.2M in total revenue for fiscal year 2025. This represents a -16.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Kymera Therapeutics, Inc.'s revenue growing?
Kymera Therapeutics, Inc. (KYMR) revenue declined by 16.7% year-over-year, from $47.1M to $39.2M in fiscal year 2025.
Is Kymera Therapeutics, Inc. profitable?
Yes, Kymera Therapeutics, Inc. (KYMR) reported a net income of $311.4M in fiscal year 2025.
What is Kymera Therapeutics, Inc.'s EBITDA?
Kymera Therapeutics, Inc. (KYMR) had EBITDA of -$341.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Kymera Therapeutics, Inc.'s gross margin?
Kymera Therapeutics, Inc. (KYMR) had a gross margin of 0.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Kymera Therapeutics, Inc.'s return on equity (ROE)?
Kymera Therapeutics, Inc. (KYMR) has a return on equity of 19.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Kymera Therapeutics, Inc.'s free cash flow?
Kymera Therapeutics, Inc. (KYMR) recorded an outflow of $234.3M in free cash flow during fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kymera Therapeutics, Inc.'s operating cash flow?
Kymera Therapeutics, Inc. (KYMR) recorded an outflow of $232.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Kymera Therapeutics, Inc.'s total assets?
Kymera Therapeutics, Inc. (KYMR) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Kymera Therapeutics, Inc.'s capital expenditures?
Kymera Therapeutics, Inc. (KYMR) invested $1.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Kymera Therapeutics, Inc. spend on research and development?
Kymera Therapeutics, Inc. (KYMR) invested $316.6M in research and development during fiscal year 2025.
What is Kymera Therapeutics, Inc.'s current ratio?
Kymera Therapeutics, Inc. (KYMR) had a current ratio of 10.47 as of fiscal year 2025, which is generally considered healthy.
What is Kymera Therapeutics, Inc.'s debt-to-equity ratio?
Kymera Therapeutics, Inc. (KYMR) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Kymera Therapeutics, Inc.'s return on assets (ROA)?
Kymera Therapeutics, Inc. (KYMR) had a return on assets of 17.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Kymera Therapeutics, Inc.'s Altman Z-Score?
Kymera Therapeutics, Inc. (KYMR) has an Altman Z-Score of 37.36, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kymera Therapeutics, Inc.'s Piotroski F-Score?
Kymera Therapeutics, Inc. (KYMR) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kymera Therapeutics, Inc.'s earnings high quality?
For every $1 of reported earnings, Kymera Therapeutics, Inc. (KYMR) used $0.75 of operating cash (-$232.9M OCF vs $311.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Kymera Therapeutics, Inc.?
Kymera Therapeutics, Inc. (KYMR) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.